FMP
Evoke Pharma, Inc.
EVOK
NASDAQ
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
2.63 USD
-0.009 (-0.342%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Matthew J. D'Onofrio MBA
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.evokepharma.comexchange
NASDAQ
Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
CIK
0001403708
ISIN
US30049G2030
CUSIP
30049G104
Address
420 Stevens Avenue
Phone
858 345 1494
Country
US
Employee
3
IPO Date
Sep 25, 2013
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
EVOK Financial Summary
CIK
0001403708
Exchange
NASDAQ
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
30049G104
ISIN
US30049G2030
Country
US
Price
2.63
Beta
0.29
Volume Avg.
17.94k
Market Cap
3.93M
Shares
-
52-Week
1.94-12.32
DCF
-0.15
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.94
P/B
-
Website
https://www.evokepharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EVOK News
It looks like there's no news available.
